HORIZON ORPHAN LLC
Patent Owner
Stats
- 27 US PATENTS IN FORCE
- 7 US APPLICATIONS PENDING
- Jan 30, 2018 most recent publication
Details
- 27 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 812 Total Citation Count
- Jul 25, 2002 Earliest Filing
- 15 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2016/0243,082 4-Methylpyrazole Formulations for Inhibiting Ethanol IntoleranceMay 02, 16Aug 25, 16[A61K]
2016/0128,954 Methods of Treating Huntington's Disease Using Cysteamine CompositionsNov 05, 15May 12, 16[A61K]
2015/0125,526 Use of Cysteamine and Derivatives Thereof to Treat Mitochondrial DiseasesNov 06, 14May 07, 15[A61K]
2012/0035,166 METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONESOct 21, 11Feb 09, 12[A01P, A61K, A01N, A61P]
2011/0189,084 Method for Treating Liver Disorders with Receptor Associated Protein (RAP) Peptide-Fucosidase Inhibitor ConjugatesJan 28, 11Aug 04, 11[A61K, A61P, C07K]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9879064 Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereofJun 23, 15Jan 30, 18[A61K, C07K]
9717738 Aerosol fluoroquinolone formulations for improved pharmacokineticsApr 18, 16Aug 01, 17[A61K, A61P]
9326936 Aerosol fluoroquinolone formulations for improved pharmacokineticsJul 17, 14May 03, 16[A61K, A61P]
9233077 Delayed release cysteamine bead formulation, and methods of making and using sameJun 17, 14Jan 12, 16[A61K]
9173851 Delayed release cysteamine bead formulation, and methods of making and using sameJun 26, 15Nov 03, 15[A61K]
9062126 Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereofSep 18, 06Jun 23, 15[A61K, C07K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2017/0007,578 Genotype Specific Methods for Treating Human Subjects Using 4-MethylpyrazoleAbandonedSep 20, 16Jan 12, 17[A61K]
2016/0331,704 Delayed Release Cysteamine Bead Formulation, and Methods of Making and Using SameAbandonedJul 26, 16Nov 17, 16[A61K]
2016/0158,170 Delayed Release Cysteamine Bead Formulation, And Methods Of Making And Using SameAbandonedFeb 12, 16Jun 09, 16[A61K]
2016/0095,827 DELAYED RELEASE CYSTEAMINE BEAD FORMULATION, AND METHODS OF MAKING AND USING SAMEAbandonedDec 11, 15Apr 07, 16[A61K]
2014/0105,985 TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATIONAbandonedDec 19, 13Apr 17, 14[A61K]
2013/0150,419 4-METHYLPYRAZOLE FORMULATIONS FOR INHIBITING ETHANOL INTOLERANCEAbandonedFeb 01, 13Jun 13, 13[A61K]
2012/0322,843 GENOTYPE SPECIFIC METHODS FOR TREATING HUMAN SUBJECTS USING 4-METHYLPYRAZOLEAbandonedJun 21, 12Dec 20, 12[A61K, A61P]
2012/0252,857 GENOTYPE SPECIFIC METHODS FOR TREATING HUMAN SUBJECTS USING 4-METHYLPYRAZOLEAbandonedJun 09, 10Oct 04, 12[A61K, A61P]
2011/0053,999 4-METHYLPYRAZOLE FORMULATIONS FOR INHIBITING ETHANOL INTOLERANCEAbandonedJun 09, 10Mar 03, 11[A61K, A61P]
2008/0021,083 4-Methylpyrazole Formulations for Inhibiting Ethanol IntoleranceAbandonedMar 03, 05Jan 24, 08[A61K, C07D, A61P]
2005/0026,823 Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissuesAbandonedJun 20, 03Feb 03, 05[A61K, C07K]
2003/0129,186 Compositions and methods for modulating blood-brain barrier transportAbandonedJul 25, 02Jul 10, 03[A61K, G01N]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.